Inhibikase Therapeutics, Inc. - Common Stock (IKT)
1.4900
-0.0400 (-2.61%)
NASDAQ · Last Trade: Nov 22nd, 3:26 AM EST
Detailed Quote
Previous Close
1.530
Open
1.570
Bid
1.500
Ask
1.530
Day's Range
1.475 - 1.660
52 Week Range
1.330 - 4.200
Volume
3,182,018
Market Cap
46.27M
PE Ratio (TTM)
3.104
EPS (TTM)
0.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
235,013
Chart
About Inhibikase Therapeutics, Inc. - Common Stock (IKT)
Inhibikase Therapeutics is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly those related to Parkinson's disease. The company aims to address the underlying mechanisms of these conditions by harnessing its proprietary drug discovery platform to identify and develop compounds that can improve patient outcomes. Their research is centered around the modulation of key biological pathways implicated in neurodegeneration, with the goal of offering new treatment options that can enhance the quality of life for individuals affected by these debilitating disorders. Read More
WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the pricing of its underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares of common stock. The shares of common stock are being sold at an offering price of $1.45 per share, and the pre-funded warrants are being sold at an offering price of $1.449 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Inhibikase has granted the underwriters a 30-day option to purchase up to an additional 10,344,827 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Inhibikase from this offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding the exercise of any pre-funded warrants. All of the securities being sold in the offering are being offered by Inhibikase. The offering is expected to close on November 24, 2025, subject to the satisfaction of customary closing conditions.
BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Inhibikase intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of common stock Inhibikase is offering, at the public offering price, less underwriting discounts and commissions. All of the securities being sold in the proposed offering are being offered by Inhibikase. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2025 and highlighted recent developments.
BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the appointment of veteran biopharma executive Timothy Pigot as the Company’s Chief Commercial and Strategy Officer.
BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 --
